1,040 results on '"Savona, Michael R."'
Search Results
252. Detection of Vaccinia DNA in the Blood Following Smallpox Vaccination
253. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups.
254. Contrast Phase Classification with a Generative Adversarial Network
255. Semi-Supervised Multi-Organ Segmentation through Quality Assurance Supervision
256. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
257. Selective Inhibition of JAK1 Primes STAT5-Driven Human Leukemia Cells for ATRA-Induced Differentiation.
258. Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase
259. 157 - Factors Affecting Low Hematopoietic Cell Transplantation Rates in TP53-Mutated MDS/AML and Predictors of Overall Survival
260. 46 - A Multi-Center Collaborative Study of Outcomes of TP53-Mutated MDS/AML Patients Following Allogeneic HCT
261. Real‐world diagnostic testing patterns for assessment of ring sideroblasts and SF3B1 mutations in patients with newly diagnosed lower‐risk myelodysplastic syndromes.
262. Treatment Patterns and Outcomes of Patients with Primary or Secondary Acute Myeloid Leukemia By Type of Site (Academic or Community/Government): A CONNECT® Myeloid Registry Study
263. Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy
264. Impact of Transfusions and Treatment Choice on Time Spent in Healthcare Facilities for Patients with Myelodysplastic Syndromes
265. TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia
266. Integrating Mosaic Chromosomal Alterations and Single-Nucleotide Variants to Predict Evolution of Clonal Hematopoiesis
267. Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN
268. TP53Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia
269. The evolving role of next generation sequencing in myelodysplastic syndromes
270. A Phase Ib/II Study of Oprozomib in Patients with Advanced Multiple Myeloma and Waldenström Macroglobulinemia
271. Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma
272. Incorporating Precision BH3 Warheads Into the Offensive Against Acute Myeloid Leukemia
273. Mitochondrial Homeostasis in AML and Gasping for Response in Resistance to BCL2 Blockade
274. Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
275. Proposed diagnostic criteria for classical chronic myelomonocytic leukemia (CMML), CMML variants and pre-CMML conditions
276. Splenomegaly Segmentation on Multi-Modal MRI Using Deep Convolutional Networks
277. An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study
278. Acceleration of spleen segmentation with end-to-end deep learning method and automated pipeline
279. SynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth
280. Discovery of Potent Myeloid Cell Leukemia-1 (Mcl-1) Inhibitors That Demonstrate in Vivo Activity in Mouse Xenograft Models of Human Cancer
281. Improving splenomegaly segmentation by learning from heterogeneous multi-source labels
282. The CDK7 inhibitor THZ1 alters RNA polymerase dynamics at the 5′ and 3′ ends of genes
283. Increased Ripk1-mediated bone marrow necroptosis leads to myelodysplasia and bone marrow failure in mice
284. High burden of clonal hematopoiesis in first responders exposed to the World Trade Center disaster
285. Luspatercept for myelodysplastic syndromes/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis
286. A Novel MCL1 Inhibitor Combined with Venetoclax Rescues Venetoclax-Resistant Acute Myelogenous Leukemia
287. Long Term Results of a Randomized Phase 2 Dose-Response Study of Guadecitabine, a Novel Subcutaneous (SC) Hypomethylating Agent (HMA), in 102 Patients with Intermediate or High Risk Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML)
288. Ivosidenib or Enasidenib Combined with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML with an IDH1 or IDH2 Mutation Is Safe, Effective, and Leads to MRD-Negative Complete Remissions
289. The BET Inhibitor INCB054329 Primes AML Cells for Venetoclax-Induced Apoptosis
290. Next Generation Myelofibrosis Risk Analysis in the Electronic Health Record
291. PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia
292. Geno-Clinical Model to Aid in the Diagnosis of Myelodysplastic Syndrome (MDS) Versus Chronic Myelomonocytic Leukemia (CMML)
293. Dasatinib Versus Imatinib in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Not Achieved an Optimal Response to 3 Months of Imatinib Therapy: Dascern
294. Factors Associated with Early Therapy Initiation in Patients (pts) with Myelodysplastic Syndromes (MDS) in the Connect® MDS/AML Disease Registry
295. BET inhibitors reduce cell size and induce reversible cell cycle arrest in AML
296. A geno-clinical decision model for the diagnosis of myelodysplastic syndromes
297. CD9 phones home with a TEM of its own
298. SynSeg-Net: Synthetic Segmentation Without Target Modality Ground Truth
299. Splenomegaly Segmentation on Multi-modal MRI using Deep Convolutional Networks
300. Germline risk of clonal haematopoiesis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.